Viromed Medical AG concludes agreement with CORIUS Group for exclusive use of cold plasma therapy with Plasma Care® – Additional earnings contribution of EUR 0.28 to EUR 0.34 per share expected

Viromed Medical AG / Key word(s): Alliance
Viromed Medical AG concludes agreement with CORIUS Group for exclusive use of cold plasma therapy with Plasma Care® – Additional earnings contribution of EUR 0.28 to EUR 0.34 per share expected

22-Apr-2024 / 13:05 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Viromed Medical AG concludes agreement with CORIUS Group for exclusive use of cold plasma therapy with Plasma Care® by Viromed – Additional earnings contribution of EUR 0.28 to EUR 0.34 per share expected from 2025 onwards

Pinneberg, 22 April 2024 – Viromed Medical AG (ISIN: DE000A3MQR65) has concluded an agreement with CORIUS Group for the exclusive use of cold plasma therapy with Plasma Care® by Viromed. This means that the pioneering therapy is now available to the 1,250,000 patients of the CORIUS Group. By using Plasma Care® by Viromed as the exclusive treatment method in one of the largest networks for dermatological and phlebological practices in Europe, Viromed Medical AG expects significant growth potential and anticipates an additional earnings contribution of EUR 0.28 to EUR 0.34 per share from 2025 onwards.

Contact Viromed Medical AG

Uwe Perbandt
CEO
Flensburger Straße 18
25421 Pinneberg
Germany
Email: kontakt@viromed-medical.de
www.viromed-medical-ag.de

22-Apr-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com